Emulsification by TPGS or Quillaja Extract Increased Absorption and Affected Metabolism of Berberine in Humans

Berberine is a botanical alkaloid used widely for the prevention of several diseases. However, the absorption rate of berberine is less than 1% in human. The objectives of this study were to determine whether emulsification by TPGS or Quillaja extract affect the absorption and metabolism of orally i...

Full description

Saved in:
Bibliographic Details
Published inCurrent developments in nutrition Vol. 5; no. Supplement_2; p. 381
Main Authors Yagiz, Yavuz, Wang, Gary, Gu, Liwei
Format Journal Article
LanguageEnglish
Published Oxford Elsevier Inc 01.06.2021
Oxford University Press
Subjects
Online AccessGet full text
ISSN2475-2991
2475-2991
DOI10.1093/cdn/nzab037_091

Cover

Abstract Berberine is a botanical alkaloid used widely for the prevention of several diseases. However, the absorption rate of berberine is less than 1% in human. The objectives of this study were to determine whether emulsification by TPGS or Quillaja extract affect the absorption and metabolism of orally ingested berberine in human volunteers. Twelve healthy subjects (7 male and 5 females, 21–50-year-old) participated this study. Each subject received 800 mg berberine in a powder form or emulsified with TPGS or Quillaja extract using a randomized crossover design with one-week washout period. Blood samples were collected at 0, 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after dose. Plasma was hydrolyzed with glucuronidase and sulfatase before total content of berberine and its metabolites were analyzed on LC/MS/MS. Free forms of metabolites were determined in plasma without hydrolysis. Pharmacokinetic parameters were calculated using a non-compartment model before they were compared by analysis of covariance. The area under the curve (AUC) and peak plasma concentration (Cmax) of berberine was 6.6 μM.hr and 0.9 μM in participants received berberine powder. They were increased to 18.3 μM.hr and 4.5 μM by TPGS emulsification and 28 μM.hr and 5.1 μM by Quillaja extract emulsification, respectively. Berberrubine and demethylberberine were major metabolites of berberine. The AUC of free Berberrubine and demethylberberine was increased by 1.9 fold and 1.6 fold by TPGS and 5.9 folds and 2.7 folds by Quillaja extract, respectively, compared to berberine powder. Participants received berberine powder had AUC of 254 μM.hr and Cmax of 33 μM for total berberrubine. TPGS emulsification increased these values to 425 μM.hr and 54 μM, while Quillaja extract increased them to 341 μM.hr and 44 μM, respectively. Significant increases of AUC and Cmax were also observed for total demethylberberine by TPGS or Quillaja extract emulsification. Emulsification of berberine with TPGS or Quillaja extract significantly increased the absorption of berberine and its metabolites in human compared to berberine supplement without emulsifiers. Florida High Tech Corridor Council and Designs for Health.
AbstractList Berberine is a botanical alkaloid used widely for the prevention of several diseases. However, the absorption rate of berberine is less than 1% in human. The objectives of this study were to determine whether emulsification by TPGS or Quillaja extract affect the absorption and metabolism of orally ingested berberine in human volunteers. Twelve healthy subjects (7 male and 5 females, 21–50-year-old) participated this study. Each subject received 800 mg berberine in a powder form or emulsified with TPGS or Quillaja extract using a randomized crossover design with one-week washout period. Blood samples were collected at 0, 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after dose. Plasma was hydrolyzed with glucuronidase and sulfatase before total content of berberine and its metabolites were analyzed on LC/MS/MS. Free forms of metabolites were determined in plasma without hydrolysis. Pharmacokinetic parameters were calculated using a non-compartment model before they were compared by analysis of covariance. The area under the curve (AUC) and peak plasma concentration (Cmax) of berberine was 6.6 μM.hr and 0.9 μM in participants received berberine powder. They were increased to 18.3 μM.hr and 4.5 μM by TPGS emulsification and 28 μM.hr and 5.1 μM by Quillaja extract emulsification, respectively. Berberrubine and demethylberberine were major metabolites of berberine. The AUC of free Berberrubine and demethylberberine was increased by 1.9 fold and 1.6 fold by TPGS and 5.9 folds and 2.7 folds by Quillaja extract, respectively, compared to berberine powder. Participants received berberine powder had AUC of 254 μM.hr and Cmax of 33 μM for total berberrubine. TPGS emulsification increased these values to 425 μM.hr and 54 μM, while Quillaja extract increased them to 341 μM.hr and 44 μM, respectively. Significant increases of AUC and Cmax were also observed for total demethylberberine by TPGS or Quillaja extract emulsification. Emulsification of berberine with TPGS or Quillaja extract significantly increased the absorption of berberine and its metabolites in human compared to berberine supplement without emulsifiers. Florida High Tech Corridor Council and Designs for Health.
Objectives Berberine is a botanical alkaloid used widely for the prevention of several diseases. However, the absorption rate of berberine is less than 1% in human. The objectives of this study were to determine whether emulsification by TPGS or Quillaja extract affect the absorption and metabolism of orally ingested berberine in human volunteers. Methods Twelve healthy subjects (7 male and 5 females, 21–50-year-old) participated this study. Each subject received 800 mg berberine in a powder form or emulsified with TPGS or Quillaja extract using a randomized crossover design with one-week washout period. Blood samples were collected at 0, 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after dose. Plasma was hydrolyzed with glucuronidase and sulfatase before total content of berberine and its metabolites were analyzed on LC/MS/MS. Free forms of metabolites were determined in plasma without hydrolysis. Pharmacokinetic parameters were calculated using a non-compartment model before they were compared by analysis of covariance. Results The area under the curve (AUC) and peak plasma concentration (Cmax) of berberine was 6.6 μM.hr and 0.9 μM in participants received berberine powder. They were increased to 18.3 μM.hr and 4.5 μM by TPGS emulsification and 28 μM.hr and 5.1 μM by Quillaja extract emulsification, respectively. Berberrubine and demethylberberine were major metabolites of berberine. The AUC of free Berberrubine and demethylberberine was increased by 1.9 fold and 1.6 fold by TPGS and 5.9 folds and 2.7 folds by Quillaja extract, respectively, compared to berberine powder. Participants received berberine powder had AUC of 254 μM.hr and Cmax of 33 μM for total berberrubine. TPGS emulsification increased these values to 425 μM.hr and 54 μM, while Quillaja extract increased them to 341 μM.hr and 44 μM, respectively. Significant increases of AUC and Cmax were also observed for total demethylberberine by TPGS or Quillaja extract emulsification. Conclusions Emulsification of berberine with TPGS or Quillaja extract significantly increased the absorption of berberine and its metabolites in human compared to berberine supplement without emulsifiers. Funding Sources Florida High Tech Corridor Council and Designs for Health.
Objectives Berberine is a botanical alkaloid used widely for the prevention of several diseases. However, the absorption rate of berberine is less than 1% in human. The objectives of this study were to determine whether emulsification by TPGS or Quillaja extract affect the absorption and metabolism of orally ingested berberine in human volunteers. Methods Twelve healthy subjects (7 male and 5 females, 21–50-year-old) participated this study. Each subject received 800 mg berberine in a powder form or emulsified with TPGS or Quillaja extract using a randomized crossover design with one-week washout period. Blood samples were collected at 0, 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after dose. Plasma was hydrolyzed with glucuronidase and sulfatase before total content of berberine and its metabolites were analyzed on LC/MS/MS. Free forms of metabolites were determined in plasma without hydrolysis. Pharmacokinetic parameters were calculated using a non-compartment model before they were compared by analysis of covariance. Results The area under the curve (AUC) and peak plasma concentration (Cmax) of berberine was 6.6 μM.hr and 0.9 μM in participants received berberine powder. They were increased to 18.3 μM.hr and 4.5 μM by TPGS emulsification and 28 μM.hr and 5.1 μM by Quillaja extract emulsification, respectively. Berberrubine and demethylberberine were major metabolites of berberine. The AUC of free Berberrubine and demethylberberine was increased by 1.9 fold and 1.6 fold by TPGS and 5.9 folds and 2.7 folds by Quillaja extract, respectively, compared to berberine powder. Participants received berberine powder had AUC of 254 μM.hr and Cmax of 33 μM for total berberrubine. TPGS emulsification increased these values to 425 μM.hr and 54 μM, while Quillaja extract increased them to 341 μM.hr and 44 μM, respectively. Significant increases of AUC and Cmax were also observed for total demethylberberine by TPGS or Quillaja extract emulsification. Conclusions Emulsification of berberine with TPGS or Quillaja extract significantly increased the absorption of berberine and its metabolites in human compared to berberine supplement without emulsifiers. Funding Sources Florida High Tech Corridor Council and Designs for Health.
Author Wang, Gary
Gu, Liwei
Yagiz, Yavuz
Author_xml – sequence: 1
  givenname: Yavuz
  surname: Yagiz
  fullname: Yagiz, Yavuz
  organization: University of Florida
– sequence: 2
  givenname: Gary
  surname: Wang
  fullname: Wang, Gary
  organization: University of Florida
– sequence: 3
  givenname: Liwei
  surname: Gu
  fullname: Gu, Liwei
  organization: University of Florida
BookMark eNqNkstvVCEUxompiXXs2i2JO5NxYOA-2JjUZvpIatRY14QLB2XkwhXurY5_fWlvE2sXoyte5_flfN_hOToIMQBCLyl5Q4lgK23CKvxWHWGNJII-QYdr3lTLtRD04MH-GTrKeUsIoUKImohDFDb95LOzTqvRxYC7Hb76ePYZx4Q_Tc57tVV482tMSo_4IugEKoPBx12OabgDVChHa0GP5f49jKqL3uUeR4vfQeoguQDYBXw-9SrkF-ipVT7D0f26QF9ON1cn58vLD2cXJ8eXS804o8tOC61aa2ndMG5r2jZroMaaFoggNVWct7xdQ8UJg6bqNBMcgLeEaqOUAcEWiMy6UxjU7qfyXg7J9SrtJCXyNjJZIpMPIivI2xkZpq4HoyEU13-wqJz8-yW4b_JrvJYtbWldOlmgV_cCKf6YII9yG6cUik3JaC0qIqpiboGquUqnmHMCK7Ub77Ivos7vaW_1iPu3odczEafhP4rFXAxlKtcOkszaQdBgXCqzlSa6PWzziNXehfKj_HfY7SVvAHo-3eU
CitedBy_id crossref_primary_10_3390_ijms25136994
ContentType Journal Article
Copyright 2021 American Society for Nutrition.
Copyright © The Author(s) on behalf of the American Society for Nutrition 2021. 2021
Copyright © The Author(s) on behalf of the American Society for Nutrition 2021.
Copyright_xml – notice: 2021 American Society for Nutrition.
– notice: Copyright © The Author(s) on behalf of the American Society for Nutrition 2021. 2021
– notice: Copyright © The Author(s) on behalf of the American Society for Nutrition 2021.
DBID 6I.
AAFTH
AAYXX
CITATION
3V.
7RV
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
KB0
M0S
NAPCQ
PHGZM
PHGZT
PIMPY
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
5PM
ADTOC
UNPAY
DOI 10.1093/cdn/nzab037_091
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
CrossRef
ProQuest Central (Corporate)
Nursing & Allied Health Database
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One
ProQuest Central Korea
Proquest Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
ProQuest Health & Medical Collection
Nursing & Allied Health Premium
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
PubMed Central (Full Participant titles)
Unpaywall for CDI: Periodical Content
Unpaywall
DatabaseTitle CrossRef
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest Central (New)
ProQuest One Academic Eastern Edition
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
DatabaseTitleList
Publicly Available Content Database


Database_xml – sequence: 1
  dbid: UNPAY
  name: Unpaywall
  url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/
  sourceTypes: Open Access Repository
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
EISSN 2475-2991
EndPage 381
ExternalDocumentID 10.1093/cdn/nzab037_091
PMC8181640
10_1093_cdn_nzab037_091
S2475299123108997
GroupedDBID .1-
.FO
0R~
7RV
7X7
8FI
8FJ
AAFWJ
AAHBH
AALRI
AAPXW
AAVAP
AAXUO
AAYWO
ABPTD
ABUWG
ABXVV
ACGFS
ACVFH
ADBBV
ADCNI
ADVLN
AEUPX
AFJKZ
AFKRA
AFPKN
AFPUW
AFRHN
AIGII
AITUG
AJUYK
AKBMS
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMNDL
AMRAJ
AOIJS
APXCP
BAYMD
BCNDV
BENPR
CCPQU
EBS
EJD
EMOBN
FDB
FYUFA
GROUPED_DOAJ
H13
HMCUK
HYE
IAO
IHR
INH
ITC
KSI
M~E
NAPCQ
O9-
OK1
PHGZM
PHGZT
PIMPY
PPXIY
PUEGO
RPM
UKHRP
Z5R
6I.
AAFTH
ABDBF
AFCTW
AFULF
BTTYL
OJZSN
ROX
TOX
0SF
AAYXX
CITATION
3V.
7XB
8FK
AZQEC
DWQXO
K9.
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
5PM
ADTOC
UNPAY
ID FETCH-LOGICAL-c3431-bc9ca8ff16734f61872e1dfd8e09061a448482e5403e75bc394ee4801cdaade93
IEDL.DBID BENPR
ISSN 2475-2991
IngestDate Mon Sep 15 10:18:45 EDT 2025
Tue Sep 30 15:59:07 EDT 2025
Fri Sep 19 20:55:38 EDT 2025
Wed Oct 01 01:49:08 EDT 2025
Thu Apr 24 23:04:50 EDT 2025
Wed Aug 28 03:17:29 EDT 2024
Fri Feb 23 02:36:48 EST 2024
Tue Aug 26 16:33:02 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue Supplement_2
Language English
License http://creativecommons.org/licenses/by-nc-nd/4.0
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
cc-by
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3431-bc9ca8ff16734f61872e1dfd8e09061a448482e5403e75bc394ee4801cdaade93
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
OpenAccessLink https://www.proquest.com/docview/3169509534?pq-origsite=%requestingapplication%&accountid=15518
PQID 3169509534
PQPubID 7121353
PageCount 1
ParticipantIDs unpaywall_primary_10_1093_cdn_nzab037_091
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8181640
proquest_journals_3169509534
crossref_citationtrail_10_1093_cdn_nzab037_091
crossref_primary_10_1093_cdn_nzab037_091
oup_primary_10_1093_cdn_nzab037_091
elsevier_sciencedirect_doi_10_1093_cdn_nzab037_091
elsevier_clinicalkey_doi_10_1093_cdn_nzab037_091
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20210601
PublicationDateYYYYMMDD 2021-06-01
PublicationDate_xml – month: 06
  year: 2021
  text: 20210601
  day: 01
PublicationDecade 2020
PublicationPlace Oxford
PublicationPlace_xml – name: Oxford
PublicationTitle Current developments in nutrition
PublicationYear 2021
Publisher Elsevier Inc
Oxford University Press
Publisher_xml – name: Elsevier Inc
– name: Oxford University Press
SSID ssj0001999609
Score 2.1498156
Snippet Berberine is a botanical alkaloid used widely for the prevention of several diseases. However, the absorption rate of berberine is less than 1% in human. The...
Objectives Berberine is a botanical alkaloid used widely for the prevention of several diseases. However, the absorption rate of berberine is less than 1% in...
Objectives Berberine is a botanical alkaloid used widely for the prevention of several diseases. However, the absorption rate of berberine is less than 1% in...
SourceID unpaywall
pubmedcentral
proquest
crossref
oup
elsevier
SourceType Open Access Repository
Aggregation Database
Enrichment Source
Index Database
Publisher
StartPage 381
SubjectTerms Dietary Bioactive Components
Metabolism
Metabolites
SummonAdditionalLinks – databaseName: Unpaywall
  dbid: UNPAY
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELdQ9wAvfA1EYSBLIAQP6ZI48cdjQR0V0qYhVmk8WbbjaIXUnZpE0P31nPNRrUNl8JjEFzm-y_l39t3PCL1RTJNYcRpE1mQQoLAwUMzwwNA0zyNluVa-OPn4hE5nyefz9LwjSfK1MFv794IcmswduiulQ8Jk6KvU92gKYfIA7c1OTsff_NFxCUsDcKpRT9zzp9SuOWerpM0jy5t5kXdrd6nWP1VRXJt0jh6gad_dNtfkx6iu9Mhc3WBy_IfveYjud8ATj1tLeYTuWPcY7Y8dBN2LNX6Lm1TQZo19H7nJoi5Kn0TU6A3rNT47_fQVL1f4S-2PKfqu8ORX5QusMDgYn9duMzzW5XLVeCCsHFw2mSJw_9hWYGnFvFzgZY4_gB6bkkM8d7jZQiifoNnR5OzjNOgOZggMAcARaCOM4qBLykiS04iz2EZZnnEbCsAHCkK-hMcWwCCxLNWGiMRaz1NjMqUyK8hTNHBLZ58hzFOhGFFC5FQkOqOcWhEaBkEWsTqP9RCNetVJ07GW-8MzCtnunhMJIyqvjegQvdsIXLaEHbubhr0tyL4OFTynBJ3tFok3Ih1EaaHH34Veg6Hd3puD3hBl50dKSSIqUk8JmAwR2zLOzes8P_j2Eze_aHjCAYtBMBwO0fuNGd_Wief_0fYFuhf7BJ9mSeoADapVbV8CQqv0q-7v_A16mT3l
  priority: 102
  providerName: Unpaywall
Title Emulsification by TPGS or Quillaja Extract Increased Absorption and Affected Metabolism of Berberine in Humans
URI https://www.clinicalkey.com/#!/content/1-s2.0-S2475299123108997
https://dx.doi.org/10.1093/cdn/nzab037_091
https://www.proquest.com/docview/3169509534
https://pubmed.ncbi.nlm.nih.gov/PMC8181640
https://doi.org/10.1093/cdn/nzab037_091
UnpaywallVersion publishedVersion
Volume 5
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2475-2991
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0001999609
  issn: 2475-2991
  databaseCode: DOA
  dateStart: 20170101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2475-2991
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0001999609
  issn: 2475-2991
  databaseCode: M~E
  dateStart: 20170101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 2475-2991
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0001999609
  issn: 2475-2991
  databaseCode: RPM
  dateStart: 20170101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVPQU
  databaseName: Health Medical collection
  customDbUrl:
  eissn: 2475-2991
  dateEnd: 20221231
  omitProxy: true
  ssIdentifier: ssj0001999609
  issn: 2475-2991
  databaseCode: 7X7
  dateStart: 20170101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl: http://www.proquest.com/pqcentral?accountid=15518
  eissn: 2475-2991
  dateEnd: 20221231
  omitProxy: true
  ssIdentifier: ssj0001999609
  issn: 2475-2991
  databaseCode: BENPR
  dateStart: 20170101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3db9MwELe27gFeEGwgCqOyBELwEJrESRw_INShbhPSqgKrVJ4if0UrSp3StILur9_ZTboVqdujk1xk5S53vzvfB0LvOBUk5GniBVoqcFCo73EqU08mcZ4HXKeC2-Lki0FyPoq-jePxHho0tTA2rbLRiU5Rq1LaGHmXBAmLbXO06Mvsj2enRtnT1WaEBq9HK6jPrsXYPjqwKjlqoYOT_mD44zbqYvG9z5oeP4x0pTJdc82FT2jms2CXedqqfrMg9P8UykdLM-Orv7wo7tin06foSQ0scW8tCc_QnjaH6KhnwKmervB77FI9XQz9CJn-dFlUNknI8QWLFb4cnv3E5Rx_X9oxRL857v9b2AIqDArE5q1rhXuiKudOw2BuYOkyQeD6hV6AJBWTaorLHJ8An1xJIZ4Y7I4IqudodNq__Hru1YMXPEkAUHhCMslT4FVCSZQnQUpDHahcpdpnYP85uHRRGmoAe0TTWEjCIq1tHxqpOFeakReoZUqjXyKcxoxTwhnLExYJlaSJZr6k4EQRLfJQtNGn5ntnsu5KbodjFNn6dJxkwKDsDoPa6MOGYLZuyLH7Ub9hYNbUmYJmzMBY7CYJNyQ1BFlDi_uJ3oJ0PLyb40Z6slpPVNmtVLcR3ZKozets_-_tO2Zy5fqAA9YCZ9dvo48b2XtoE6_u38Rr9Di0OTsuynSMWov5Ur8B0LUQHbRPx7RT_08dF7qA1Wgw7P26AT4mNUA
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF5V6aFcEFAQgRZW4iE4mNhev_ZQoRRSUtpEBVKpN3dfFqmcdYgTlfDj-G3Mbuy0QUp76tGPsVae2XntzDcIvWYxJz5LIsdTQkKAErsOi0XiiCjMMo-phDPTnNzrR93T4OtZeLaB_ta9MKasstaJVlHLQpgceYt4EQ0NOFrwcfzLMVOjzOlqPUKDVaMV5J6FGKsaO47U_BJCuHLv8DPw-43vH3QGn7pONWXAEQSsp8MFFSyBhUUxCbLIS2JfeTKTiXIpGDsG8UuQ-Ao8G6LikAtCA6UM6IqQjEllwJjABGyC2-EHDbS53-mffL_K8ph4wqU1phAlLSF1S_9h3CVx6lJvnTlc6bYzTu__JZtbMz1m80uW59fs4cEDdL9yZHF7IXkP0YbSj9B2W0MQP5rjt9iWltqc_TbSndEsL01RkpUDzOd4cPLlBy4m-NvMjD26YLjze2oatjAoLFMnryRu87KYWI2GmYZLW3kC93tqCpKbD8sRLjK8D3JhWxjxUGN7JFE-Rqd3woInqKELrZ4inISUxYRRmkU04DJKIkVdEUPQRhTPfN5EH-r_nYoKBd0M48jTxWk8SYFB6TUGNdG7JcF4AQCy_lW3ZmBa97WCJk7BOK0n8ZcklcuzcGVuJnoF0nH7anZq6UkrvVSmV7uoieIViVp-zuCNrz7Rw58Wdxx8Owiu3SZ6v5S92xbx7OZFvERb3UHvOD0-7B89R_d8Uy9kM1w7qDGdzNQuOHxT_qLaVRid3_VG_gdHwW5T
linkToUnpaywall http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELdQ9wAvfA1EYSBLIAQP6ZI48cdjQR0V0qYhVmk8WbbjaIXUnZpE0P31nPNRrUNl8JjEFzm-y_l39t3PCL1RTJNYcRpE1mQQoLAwUMzwwNA0zyNluVa-OPn4hE5nyefz9LwjSfK1MFv794IcmswduiulQ8Jk6KvU92gKYfIA7c1OTsff_NFxCUsDcKpRT9zzp9SuOWerpM0jy5t5kXdrd6nWP1VRXJt0jh6gad_dNtfkx6iu9Mhc3WBy_IfveYjud8ATj1tLeYTuWPcY7Y8dBN2LNX6Lm1TQZo19H7nJoi5Kn0TU6A3rNT47_fQVL1f4S-2PKfqu8ORX5QusMDgYn9duMzzW5XLVeCCsHFw2mSJw_9hWYGnFvFzgZY4_gB6bkkM8d7jZQiifoNnR5OzjNOgOZggMAcARaCOM4qBLykiS04iz2EZZnnEbCsAHCkK-hMcWwCCxLNWGiMRaz1NjMqUyK8hTNHBLZ58hzFOhGFFC5FQkOqOcWhEaBkEWsTqP9RCNetVJ07GW-8MzCtnunhMJIyqvjegQvdsIXLaEHbubhr0tyL4OFTynBJ3tFok3Ih1EaaHH34Veg6Hd3puD3hBl50dKSSIqUk8JmAwR2zLOzes8P_j2Eze_aHjCAYtBMBwO0fuNGd_Wief_0fYFuhf7BJ9mSeoADapVbV8CQqv0q-7v_A16mT3l
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Emulsification+by+TPGS+or+Quillaja+Extract+Increased+Absorption+and+Affected+Metabolism+of+Berberine+in+Humans&rft.jtitle=Current+developments+in+nutrition&rft.au=Yagiz%2C+Yavuz&rft.au=Wang%2C+Gary&rft.au=Gu%2C+Liwei&rft.date=2021-06-01&rft.pub=Oxford+University+Press&rft.eissn=2475-2991&rft.volume=5&rft.spage=381&rft_id=info:doi/10.1093%2Fcdn%2Fnzab037_091
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2475-2991&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2475-2991&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2475-2991&client=summon